Governance and Society Leadership

Board of Directors

2019 - 2020

President, Justin Hanes, PhD

Dr. Hanes is the Lewis J. Ort Professor of Ophthalmology with joint appointments in Biomedical Engineering, Chemical & Biomolecular Engineering, Environmental Health Sciences, Neurosurgery, and Oncology at the Johns Hopkins University. His degrees are in Chemical Engineering from UCLA (B.S.) and MIT (Ph.D.), and he has completed a postdoctoral fellowship in Oncology and Neurosurgery at Johns Hopkins prior to beginning his faculty position in 1998. Professor Hanes is the Director of the Center for Nanomedicine at the Johns Hopkins University School of Medicine. He is also Director of Therapeutics for the Institute for NanoBioTechnology (INBT), which includes more than 170 faculty members and spans several divisions of the university.

Immediate Past-President, Maria José Alonso, PhD

Dr. Alonso is Professor of Pharmaceutical Technology at the University of Santiago de Compostela (Spain). Her lab has pioneered numerous discoveries in the field of Nanopharmaceutical Technology and nanomedicine. She is the author of over 260 scientific contributions with more than 14,900 cites (H factor 68) and the inventor of 20 patent families. Prof. Alonso is also a fellow of the American Institute for Medical and Biological Engineering (AIMBE), a member of three Academies in Spain and a member of the US National Academy of Medicine (NAM). She is Editor-in-Chief of the Drug Delivery and Translational Research Journal.

President-Elect, Yvonne Perrie, PhD

Yvonne Perrie is Professor in Drug Delivery within the Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, Scotland. She gained her PhD from the University of London (1998) investigating the role of liposomes for drug delivery. She then worked developing liposome drug delivery platform technology. Yvonne joined Aston University in 2000 and was appointed Professor in Drug Delivery in 2007. In 2016, Yvonne moved to the University of Strathclyde as part of the Global Talent Appointment Programme. Yvonne’s research is multi-disciplinary and is focused on the development of drug delivery systems to facilitate the delivery of drugs and vaccines.

Secretary, Andy Lewis, PhD

Andy Lewis, BPharm (Hons) MAPS Ph.D. is VP Pharmaceutical Sciences at Quotient Sciences where he leads a team of 120 scientists working on formulation development, clinical manufacturing and pharmaceutical analysis for clients’ drug product programs. Prior to this, he was Director Novel Drug Delivery Technologies at Ipsen (France) where he had global responsibility for product development utilizing novel formulation technologies and devices. He has also helped set up and grow two venture capital-funded start-ups, RegenTec and Critical Pharmaceuticals, where he led the development and commercialization of novel technologies in the fields of tissue engineering and drug delivery, taking them from concept into clinical development. He has a particular interest in overcoming drug delivery challenges, including sustained release and transmucosal delivery of proteins and peptides, and he has filed a number of patents. He is a member of the Academy of Pharmaceutical Scientists of Great Britain, and has previously served on the Membership Committee, Board of Scientific Advisors and was Director-at-Large of the Controlled Release Society (CRS).

Treasurer, David Putnam, PhD

Dr. Putnam is Professor of Biomedical Engineering and Professor of Chemical and Biomolecular Engineering at Cornell University, Ithaca, NY. He received his graduate training at the University of Utah. He was an NIH postdoctoral fellow in the Department of Chemical Engineering at MIT in the laboratory of Professor Robert Langer. He held a joint appointment at MIT and as a Scientific co-Founder of TransForm Pharmaceuticals, Inc., which was acquired by Johnson & Johnson in March, 2005. In 2008-2009 he was an Entrepreneur-in-Residence at PureTech Ventrures in Boston, MA where he focused on emerging technologies in the field of drug delivery.

Treasurer-Elect, Cornell Stamoran, PhD

Cornell Stamoran has thirty years’ experience across a broad range of disciplines, including accounting and finance, strategy, M&A, innovation, IT, advocacy (IR, PR, Gov’t), and sales and marketing. Cornell began his career with five years in Arthur Andersen & Co.’s accounting and audit practice. Cornell then joined drug delivery provider R.P. Scherer Corporation, first focusing on finance and IT, then migrating to strategy and innovation. Following Cardinal Health’s acquisition of Scherer, Cornell continued his migration to growth-related functions, including building global business development and sales operations teams, establishing a strategic marketing function, and supporting M&A. Following Catalent’s spin-out in 2007, Cornell has been accountable for branding and marketing; public, investor, and government relations; market intelligence and strategy; and innovation and regulatory policy, including as a member of the industry negotiating team for GDUFA reauthorization. Cornell holds a B.S.A. with honors from the University of Michigan (accounting and finance), and a Ph.D. in history. He holds/has held a variety of professional certifications including Certified Public Accountant, Certified Management Accountant, Certified Information Systems Auditor, Certified Licensing Professional, Certified Systems Engineer, Lean-Six Sigma Green Belt, and is completing a RAPS regulatory affairs certificate. Cornell currently serves as Co-Chair of the Catalent Applied.

Director-at-Large, Ilva Rupenthal, PhD (3-year term through 2020)

Ilva Rupenthal.jpgDr. Rupenthal is associate Professor in the Department of Opthalmology and Director of the Buchanan Ocular Therapeutics Unit at the University of Auckland. She received a BPharm from the Philipps-University of Marburg, Germany, in 2003 and completed a PhD on ‘Ocular delivery of antisense oligonucleotides’ with the School of Pharmacy and the Department of Ophthalmology, University of Auckland, in 2008. In 2010, Dr. Rupenthal was awarded a prestigious three-year New Zealand Science and Technology Postdoctoral Fellowship to establish an ocular pharmaceutics group within the New Zealand National Eye Centre. In 2013, she then received a prestigious $500,000 HRC Sir Charles Hercus Research Fellowship to continue her innovative research into stimuli-responsive ocular implants. Dr Rupenthal has received several awards including the 2016 HRC Celebrating Research Excellence Award and the 2014 University of Auckland Early Career Research Excellence Award, while also being a winner of the Spark Entrepreneurship Ideas Challenges in 2012 and 2014.

Director-at-Large, Twan Lammers, DSc, PhD (3-year term through 2021)

Dr. Lammers obtained a D.Sc. degree in radiation oncology from Heidelberg University in 2008 and a Ph.D. degree in pharmaceutics from Utrecht University in 2009. In the same year, he started the Nanomedicine and Theranostics group at the Institute for Experimental Molecular Imaging at RWTH Aachen University. In 2014, he was promoted to full professor at the faculty of medicine at RWTH Aachen University Hospital. Professor Lammers is also affiliated with the Universities of Twente and Utrecht in The Netherlands. He has published over 150 research articles and reviews and received awards, including the CRS Young Investigator Award. He is associate editor for Europe at the Journal of Controlled Release and serves on the editorial board of multiple other journals.

Director-at-Large, Steven Little, PhD (3-year term through 2021)

Dr. Little is currently the William Kepler Whiteford Endowed Professor of Chemical Engineering, Bioengineering, Pharmaceutical Sciences, Immunology, Ophthalmology and The McGowan Institute for Regenerative Medicine at the University of Pittsburgh. Steve also has served as the 12th Chairman of the Department of Chemical Engineering since 2012. Dr. Little is a Co-Founder of Qrono Inc. (a biomedical startup focused on controlled release-based cancer treatments) and OTERO Inc. (a biomedical startup focused on ocular drug delivery). His work has been highlighted in a wide range of journals including Journal of Controlled Release, Journal of the American Chemical Society, Angewandte Chemie, Proceedings of the National Academy of Sciences, ACS Nano, Advanced Materials, Biomaterials and Nature Methods. He has received a number of honors for his research. Steve currently serves as the Representative for CRS Focus Groups.

Director-at-Large, Alexander Kabanov, PhD (3-year term through 2022)

Alexander Kabanov is a Mescal S. Ferguson Distinguished Professor at the Eshelman School of Pharmacy, the University of North Carolina at Chapel Hill, where he heads the Center for Nanotechnology in Drug Delivery and the Carolina Institute for Nanomedicine. He graduated from the Moscow State University in 1984, where he also received Ph.D. in 1987 and D.Sc. in 1990. Since 1994 he has worked in the United States. He introduced new concepts in nanomedicine including polymeric micelles, DNA/polycation complexes, block ionomer complexes, nanogels, nanoparticle-macrophage carriers and exosomes for delivery of small drugs, nucleic acids and polypeptides to treat cancers and diseases of the central nervous system. He invented the first polymeric micelle technology for cancer drug delivery to enter the clinical trials and co-founded pharmaceutical companies to develop products based on polymeric micelles. He published over 300 scientific papers, holds 35 US patents and was named the Highly Cited Researcher in Pharmacology and Toxicology. He has founded the Nanomedicine and Drug Delivery symposium series (www.nanodds.org), Carolina Nanoformulation Workshop, chaired Gordon Research Conferences, served on the CRS Board of Scientific Advisors, CRS Bioactive Materials Track Program Chair, and NIH study section chair. He received numerous awards and was elected to Academia Europaea, fellow of the CRS, NAI and AIMBE.

Director-at-Large, Katie Whitehead, PhD (3-year term through 2022)

Kathryn A. Whitehead is an Associate Professor and Dean’s Career Fellow in the Departments of Chemical Engineering and Biomedical Engineering (courtesy) at Carnegie Mellon University. Her lab develops RNA and protein drug delivery systems and has a long-term goal of predicting the behavior of delivery materials in humans. She received an H.B.Ch.E Degree with Distinction from the University of Delaware (2002) and a Ph.D. in chemical engineering from the University of California, Santa Barbara (2007) before serving as an NIH Ruth L. Kirschstein Postdoctoral Fellow at the Massachusetts Institute of Technology (2008 – 2012). Prof. Whitehead is the recipient of numerous awards, including the NIH Director’s New Innovator Award, the DARPA Young Faculty Award, the DARPA Director’s Fellowship, the George Tallman Ladd Research Award, the CMBE Young Innovator Award, and the Kun Li Award for Excellence in Education. Prof. Whitehead was named as a Pioneer on the MIT Technology Review’s Innovators Under 35 list in 2014 as well as one of the Brilliant Ten by Popular Science in 2015. Her publications have been cited over 5,000 times, and several of her patents have been licensed and sublicensed for reagent and therapeutic use.